Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MYE Symphony: A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors

NCT05969041 is registered in ClinicalTrials.gov with Myeloid Therapeutics as lead sponsor.

NCT NCT05969041
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05969041 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MYE Symphony: A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors
Lead sponsor
Myeloid Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
August 2, 2023
Completion date
August 31, 2028
Enrollment
48 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

epithelial tumors, malignant